SCHEMBL24036286

SCHEMBL24036286

Cn1cc(C(=O)NCc2nc(-c3cc4c(N[C@H]5CCN(C(C)(C)C)C[C@H]5F)cccc4n3CC(F)(F)F)no2)cn1

nearest known ligand 0.34

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
MAPK8 P45983 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.32
MAPT P10636 3/20 0.32
KDM1A O60341 1/20 0.31
ROCK2 O75116 1/20 0.31
TP53 P04637 1/20 0.30
PADI4 Q9UM07 1/20 0.30
KMT2A Q03164 1/20 0.30
CNR1 P21554 1/20 0.30
KCNH2 Q12809 1/20 0.30
MMP13 P45452 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24035883 1.00 LMNA (0.34) LMNAHPGDMAPK8SMN1; SMN2MAPT
SCHEMBL24035886 1.00 LMNA (0.34) LMNAHPGDMAPK8SMN1; SMN2MAPT
SCHEMBL24036282 0.94 MAPT (0.31) MAPTTP53
SCHEMBL24035352 0.94 MAPT (0.31) MAPTTP53
SCHEMBL24853795 0.94 MAPT (0.31) MAPTTP53
SCHEMBL24036047 0.93 LMNA (0.36) LMNAHPGDMAPK8SMN1; SMN2MAPT
SCHEMBL24035372 0.92 CNR1 (0.32) LMNAHPGDSMN1; SMN2MAPTPADI4
SCHEMBL24853078 0.92 CNR1 (0.32) LMNAHPGDSMN1; SMN2MAPTPADI4
SCHEMBL24035374 0.92 CNR1 (0.32) LMNAHPGDSMN1; SMN2MAPTPADI4
SCHEMBL24036099 0.90 PADI4 (0.31) MAPTPADI4CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240043436-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2024-02-08 US disclosed
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 US disclosed
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 US disclosed
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 US disclosed
EP-4149459-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV Pharmaceuticals, Inc. (US) 2023-03-22 EP disclosed
US-20230002403-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-01-05 US disclosed
US-20230002403-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-01-05 US disclosed
WO-2021231474-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2021-11-18 WO disclosed
WO-2021231474-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2021-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002403-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS LMNA 2728/4885HPGD 1062/4885MAPK8 1213/4885
US-11807644-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS LMNA 2728/4885HPGD 1062/4885MAPK8 1213/4885
US-20240043436-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS LMNA 2728/4885HPGD 1062/4885MAPK8 1213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.